Disruptive Pharma AB

Rewarding day at A Working Lab! We had an incredible strategy meeting with the board of Disruptive Pharma, and the energy was electric! It was a privilege to be joined by the brilliant Maria Strömme (online), along with other talented professionals from a range of diverse backgrounds. When people with such different expertise come together, great things happen – new ideas emerge, fresh perspectives challenge the status quo, and innovation takes flight. Our discussions were inspiring, productive, and full of potential. We are confident the outcomes will drive impactful results for the future of the pharma industry.

A Big Thank You to Life Science Sweden and specially to Maria Eriksson for an Outstanding Event! We at Disruptive Pharma are thrilled to have participated in the 12th Edition of New Updates in Drug Formulation & Bioavailability hosted by Life Science Sweden. This event was an excellent platform for bridging the gap between science and industry, bringing together top R&D professionals and pharma industry leaders. Special thanks to all the speakers and participants who contributed to the engaging discussions on the latest advancements in drug formulations and bioavailability. These innovations are critical for developing safer, more effective, and more affordable drugs, which is a goal we are deeply committed to. We were particularly proud to have our own Principal Scientist, Jonas Fagerberg, share insights on our latest developments at Disruptive Pharma. The exchange of ideas and knowledge at this event has certainly inspired us as we continue to push the boundaries in pharmaceutical formulation. special thanks to the amazing moderator:Korbinian Löbmann #Pharmaceuticals #DrugDevelopment #Bioavailability #Innovation #LifeScienceSweden #DisruptivePharma

Today, our Principal Scientist, Jonas Fagerberg delivered an insightful talk at the New Updates in Drug Formulation and Bioavailability conference in Copenhagen, focusing on the future of disruptive pharma. During the session, our scientist highlighted the groundbreaking potential of our mesoporous magnesium carbonate (MMC) as a versatile drug delivery carrier for small molecule oral drugs. One of the key discussions centered around our latest case study on Sorafenib, showcasing how MMC can enhance bioavailability and efficacy, potentially transforming treatment options. We're looking forward to sharing more details soon—stay tuned for the full presentation, which will be published shortly! #DrugDelivery #Bioavailability #Copenhagen #OralDrugs #MesoporousMagnesiumCarbonate

Sorafenib has been a cornerstone treatment for hepatocellular carcinoma (HCC), one of the most common types of liver cancer. However, like many Class II drugs, it faces significant challenges in terms of solubility and bioavailability, limiting its effectiveness. Our Mesoporous Magnesium Carbonate, or MMC, significantly enhances the dissolution, solubility and bioavailability of drugs like sorafenib. By converting sorafenib into an amorphous state using MMC, we’ve been able to overcome its solubility limitations in our preclinical studies.

As we return from the summer break, we are pleased to share insights from our collaboration with the Ångströmlaboratoriet. This partnership allows us to access their advanced facilities and expertise, crucial for our ongoing research on Mesoporous Magnesium Carbonate (MMC) for pharmaceutical applications. We conducted a detailed analysis of the particle size distribution of MMC using the Malvern Mastersizer 3000. We utilized both the Dry Method (Aero S) and Wet Analysis (Hydro Ev), ensuring precise and reproducible results. Both techniques are well-suited for working with dry powder MMC. The findings on particle size distribution are significant for understanding release of active compounds from drug delivery systems. These studies form the foundation for further advancements in pharmaceutical formulations and drug delivery mechanisms. We look forward to continuing our research and sharing more developments in the near future. #PharmaceuticalResearch #DrugDeliverySystems #MMC #ParticleSizeDistribution #Ångströmlaboratoriet

Disruptive Pharma AB is innovating in the field of drug delivery to enhance the efficacy and safety of medications. If you are interested in new solutions for increasing bioavailability learn more here:

🎉 **Exciting News from Disruptive Pharma!** 🎉 We're thrilled to announce that our beamtime proposal at MAX IV has been accepted! This gives us an incredible opportunity to delve into the physical state and spatial distribution of active pharmaceutical ingredients (APIs) loaded in mesoporous magnesium carbonate (MMC). Our team, consisting of skilled scientists from both Disruptive Pharma and RISE Research Institutes of Sweden will conduct a cutting-edge scanning X-ray diffraction (XRD) experiment at the NanoMAX beamline at MAX IV. Utilizing a nano-focused X-ray beam, we aim to gain unparalleled insights into the physical state and spatial distribution of APIs within MMC particles. This detailed understanding will significantly contribute to refining drug delivery systems and enhancing therapeutic efficacy. Stay tuned for updates as we embark on this exciting journey to revolutionize drug delivery systems! Special thanks to: Petru Niga,Simone Sala, Jenny Rissler, Jonas Fagerberg #DrugDelivery #Beamtime #MAXIV #NanoMAX #XRayDiffraction #InnovationInPharma #Collaboration #RISE #Vinnova #bioavailability

Did you know MMC was once considered impossible to synthesize? The inception of Disruptive Pharma was sparked by the discovery of MMC technology in 2012 at Uppsala University by professor Maria Strömme and her group. This breakthrough in synthesizing a novel form of magnesium carbonate, previously thought impossible, marked the beginning of our journey. With exclusive rights to this technology for pharmaceutical applications and two pending patent families, we are at the forefront of drug delivery innovation. Our long-term ambition is not only to dominate the market for drug formulations but also to revolutionize how drugs are developed and delivered. By offering solutions that improve solubility, enhance bioavailability, and reduce the need for excipients, we are setting new standards in the pharmaceutical industry. #drugdelivery #formulation #bioavailability #solubility

MMC technology by Disruptive Pharma AB for Amorphization of Poorly Water-Soluble Drugs

Do you have a challenging molecule to formulate? do you work with BCS class II drugs? our patented Mesoporous Magnesium carbonate technology owned by Disruptive Pharma AB might be your solution! #solubility #bioavailability #drugdelivery #drugformulation